Regulation of the production and action of leukotrienes by MK-571 and MK-886.
Ford-Hutchinson
A W
AW
Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Quebec, Canada.
D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy; D016084:Bronchoconstriction / Q000187:drug effects; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D004311:Double-Blind Method; D004789:Enzyme Activation; D006168:Guinea Pigs; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D015289:Leukotrienes / Q000096:biosynthesis*; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology* / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000187:drug effects; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000037:antagonists & inhibitors*; D002722:Chlorobenzenes
D058927:5-Lipoxygenase-Activating Proteins; D001094:Arachidonate 5-Lipoxygenase; D002352:Carrier Proteins; D007211:Indoles; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; C548592:ALOX5AP protein, human; C060893:MK-886; D002722:Chlorobenzenes; C059141:verlukast